Journal of Clinical Oncology, Vol 21, Issue 19
(October), 2003: 3647-3650
© 2003 American Society for Clinical Oncology
Postoperative Nomogram for Disease-Specific Survival After an R0 Resection for Gastric Carcinoma
Michael W. Kattan,
Martin S. Karpeh,
Madhu Mazumdar,
Murray F. Brennan
From the Departments of Urology, Epidemiology and Biostatistics, and Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.
Address reprint requests to Murray F. Brennan, MD, Memorial Sloan-Kettering Cancer Center, Department of Surgery, 1275 York Ave, C1275 New York, NY 10021; e-mail: brennanm{at}mskcc.org.
Purpose: Few published studies have addressed individual patient risk after R0 resection for gastric cancer. We developed and internally validated a nomogram that combines these factors to predict the probability of 5-year gastric cancerspecific survival on the basis of 1,039 patients treated at a single institution.
Methods: Nomogram predictor variables included age, sex, primary site (distal one-third, middle one-third, gastroesophageal junction, and proximal one-third), Lauren histotype (diffuse, intestinal, mixed), number of positive lymph nodes resected, number of negative lymph nodes resected, and depth of invasion. Death as a result of gastric cancer was the predicted end point. The concordance index was used as an accuracy measure, with bootstrapping to correct for optimistic bias. Calibration plots were constructed.
Results: Gastric cancerspecific survival at 5 years was 50%. A nomogram was constructed on the basis of a Cox regression model. The bootstrap-corrected concordance index was 0.80. When compared with the predictive ability of American Joint Committee on Cancer stage, the nomogram discrimination was superior (P < .001). Nomogram calibration appeared to be excellent.
Conclusion: A nomogram was developed to predict 5-year disease-specific survival after R0 resection for gastric cancer. This tool should be useful for patient counseling, follow-up scheduling, and clinical trial eligibility determination.
Supported by a grant from the Gelb Foundation.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
D. A. Anaya, G. Lahat, X. Wang, L. Xiao, P. W. Pisters, J. N. Cormier, K. K. Hunt, B. W. Feig, D. C. Lev, and R. E. Pollock
Postoperative nomogram for survival of patients with retroperitoneal sarcoma treated with curative intent
Ann. Onc.,
July 21, 2009;
(2009)
mdp298v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. F. Shariat, P. I. Karakiewicz, G. Godoy, and S. P. Lerner
Review: Use of nomograms for predictions of outcome in patients with advanced bladder cancer
Therapeutic Advances in Urology,
April 1, 2009;
1(1):
13 - 26.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S. F. Shariat, P. I. Karakiewicz, N. Suardi, and M. W. Kattan
Comparison of Nomograms With Other Methods for Predicting Outcomes in Prostate Cancer: A Critical Analysis of the Literature
Clin. Cancer Res.,
July 15, 2008;
14(14):
4400 - 4407.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. I. Khushalani
Cancer of the Esophagus and Stomach
Mayo Clin. Proc.,
June 1, 2008;
83(6):
712 - 722.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Weiser, R. G. Landmann, M. W. Kattan, M. Gonen, J. Shia, J. Chou, P. B. Paty, J. G. Guillem, L. K. Temple, D. Schrag, et al.
Individualized Prediction of Colon Cancer Recurrence Using a Nomogram
J. Clin. Oncol.,
January 20, 2008;
26(3):
380 - 385.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. G. Wierda, S. O'Brien, X. Wang, S. Faderl, A. Ferrajoli, K.-A. Do, J. Cortes, D. Thomas, G. Garcia-Manero, C. Koller, et al.
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia
Blood,
June 1, 2007;
109(11):
4679 - 4685.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-Y. Wu, M.-S. Wu, E.-P. Chiang, Y.-J. Chen, C.-J. Chen, N.-H. Chi, Y.-T. Shih, G.-H. Chen, and J.-T. Lin
Plasma Matrix Metalloproteinase-9 Level Is Better than Serum Matrix Metalloproteinase-9 Level to Predict Gastric Cancer Evolution
Clin. Cancer Res.,
April 1, 2007;
13(7):
2054 - 2060.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. W. Gee and D. W. Rattner
Management of Gastroesophageal Tumors
Oncologist,
February 1, 2007;
12(2):
175 - 185.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. F. Shariat, P. I. Karakiewicz, G. S. Palapattu, G. E. Amiel, Y. Lotan, C. G. Rogers, A. Vazina, P. J. Bastian, A. Gupta, A. I. Sagalowsky, et al.
Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy.
Clin. Cancer Res.,
November 15, 2006;
12(22):
6663 - 6676.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Lagarde, F. J.W. ten Kate, J. B. Reitsma, O. R.C. Busch, and J. J. B. van Lanschot
Prognostic Factors in Adenocarcinoma of the Esophagus or Gastroesophageal Junction
J. Clin. Oncol.,
September 10, 2006;
24(26):
4347 - 4355.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
International Bladder Cancer Nomogram Consortium
Postoperative Nomogram Predicting Risk of Recurrence After Radical Cystectomy for Bladder Cancer
J. Clin. Oncol.,
August 20, 2006;
24(24):
3967 - 3972.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. R. Ferrone, M. W. Kattan, J. S. Tomlinson, S. P. Thayer, M. F. Brennan, and A. L. Warshaw
Validation of a Postresection Pancreatic Adenocarcinoma Nomogram for Disease-Specific Survival
J. Clin. Oncol.,
October 20, 2005;
23(30):
7529 - 7535.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. D. Smith, R. R. Schwarz, and R. E. Schwarz
Impact of Total Lymph Node Count on Staging and Survival After Gastrectomy for Gastric Cancer: Data From a Large US-Population Database
J. Clin. Oncol.,
October 1, 2005;
23(28):
7114 - 7124.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. P.M. Jansen, H. Boot, M. Verheij, and C. J.H. van de Velde
Optimal Locoregional Treatment in Gastric Cancer
J. Clin. Oncol.,
July 10, 2005;
23(20):
4509 - 4517.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Ajani
Operate on My Stomach Cancer? Oh, No--Not You, or Not Yet!
J. Clin. Oncol.,
May 1, 2004;
22(9):
1763 - 1764.
[Full Text]
[PDF]
|
 |
|
|